Second-line therapy for non-small-cell lung cancer

Clinical Lung Cancer

Volumn 10, Issue 2, 2009, Pages 91-98

  Arango, Belisario A ^a   Castrellon, Aurelio B ^a,b   Santos, Edgardo S ^a   Raez, Luis E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Bevacizumab; Bortezomib; Cetuximab; Docetaxel; Erlotinib; Gefitinib; Lapatinib; Pemetrexed; Pralatrexate; Sorafenib; Sunitinib; Temsirolimus; Vandetanib

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; LAPATINIB; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PRALATREXATE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VANDETANIB;

ADENOCARCINOMA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLITIS; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FACE PAIN; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; HEAD AND NECK CARCINOMA; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEUKOPENIA; LIVER TOXICITY; LOADING DRUG DOSE; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; LUNG HEMORRHAGE; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; QT PROLONGATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; SOLID TUMOR; THROMBOCYTOPENIA; UPREGULATION;

EID: 65349110307     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.011     Document Type: Review

References (75)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Schiller JH, Harrington D, Belani P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
3. Fossella F, Pereira JR, Von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol 2003; 21:3016-24.
4. Scagliotti G V, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-91.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaci-zumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50.
6. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancers (NSCLC) following failure on 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCICCTG) trial. J Clin Oncol 2004; 22(suppl):622s (Abstract 7022).
7. Herbst RS, Johnson DH, Mininberg E, et al. Phase II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-55.
8. Fossella F V, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 1995; 13:645-51.
9. Burris H, Eckardt J, Fields S, et al. Phase II trials of Taxotere with non-small cell lung cancer. Proc Am Soc Clin Oncol 1993; 12:335a (Abstract 1116).
10. Gandara DR, Vokes E, Green M, et al. Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer: A confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol 1997; 16:454a (Abstract 1632).
11. Robinet G, Kleisbauer J P, Thomas P, et al. Phase II study of docetaxel (Taxotere) in first-and second-line NSCLC. Proc Am Soc Clin Oncol 1997; 16:480a (Abstract 1726).
12. Fossella F V, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced nonsmall-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-62.
13. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-103.
14. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005; 23:8389-95.
15. Fidias P, Dakhil S, Lyss A, et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: updated report with survival. J Clin Oncol 2007; 25(18 suppl):388s (Abstract LBA7516).
16. Tas F, Demir C, Camlica H, et al. Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial. Med Oncol 2004; 21:233-40.
17. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57:1116-23.
18. Chen VJ, Bawley JR, Gossett L, et al. Activity of LY231514 against several enzymes in the folate-dependent pathways. Proc Am Assoc Cancer Res 1996; 37:2598.
19. Solomon B, Bunn Jr PA. Clinical activity of Pemetrexed: a multitargeted antifolate anticancer agent. Future Oncol 2005; 1:733-46.
20. Rusthoven J, Eisenhauer E, Butts C, et al. Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1999; 17:1194-9.
21. Clarke S, Millward M, Findlay M, et al. Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC). Ann Oncol 1998; 9(suppl 4):86.
22. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of peme-trexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-97.
23. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced nonsmall cell lung cancer (NSCLC). Eur J Cancer 2007; 5(suppl):363 (Abstract P#6521).
24. Cullen MH, Zatloukal P, Sörenson S, et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008; 19:939-45.
25. Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007; 13:2675-83.
26. Ciuleanu TE, Brodowicz T, Belani C P, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol 2008; 26(15 suppl):426s (Abstract 8011).
27. Waples JM, Auerbach M, Boccia R, et al. A phase II study of oxaliplatin and peme-trexed plus bevacizumab in advanced non-squamous non-small cell lung cancer. J Clin Oncol 2007; 25(18 suppl):685s (Abstract 18025).
28. Molina JR. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 2008; 11:508-21.
29. Azzoli CG, Krug L, Miller V, et al. Phase I study of the antifolate pralatrexate given with vitamin B12 and folic acid supplementation in patients with advanced non small cell lung cancer. J Clin Oncol 2007; 25(18 suppl):608s (Abstract 13006).
30. Clinicaltrials.gov [Web site]. Study of non-small cell lung cancer after failure of at least 1 prior platinum-based treatment. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT00606502?term=pralatrexate&rank= 3. Accessed: January 29, 2009.
31. Ulrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61:203-12.
32. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265:7709-12.
33. Wikstrand CJ, Bigner DD. Prognostic applications of the epidermal growth factor receptor and its ligands, transforming growth factor-alfa. J Natl Cancer Inst 1998; 90:799-800.
34. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21:2237-46.
35. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA. 2003; 290:2149-58.
36. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37.
37. Bell D W, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23:8081-92.
38. Lee DH, Han JY, Yu SY, et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol 2006; 1:965-71.
39. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by OSI-774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57:4838-48.
40. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-79.
41. Clark GM, Perez-Soler R, Siu L, et al. Rash severity is predictive of increased survival with erlotinib HCL. Proc Am Soc Oncol 2003; 22:196.
42. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib patients with non-small cell lung cancer. J Clin Oncol 2004; 22:3238-47.
43. Shepherd FA, Pereira J, Ciuleanu TE, et al. Erlotinib in previously treated non-small-cell lung cancer. New Eng J Med 2005; 2:123-32.
44. Presta L, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothe-lial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-9.
45. Jung YD, Mansfield P F, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in nude mouse model. Eur J Cancer 2002; 38:1133-40.
46. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-47.
47. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER1/Epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-55.
48. Fehrenbacher L, O'Neill V, Belani C P, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 200; 24(18 suppl):379s (Abstract 7062).
49. Jalal SI, Waterhouse D, Edelman M, et al. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): A phase I-IIa dose-ranging study from the Hossier Oncology Group. J Clin Oncol 2007; 25(18 suppl):432s (Abstract 7698).
50. Belani C P, Ramalingam S, Schreeder M, et al. Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):420s (Abstract 7643).
51. Pirker R, Szczesna A, von Pawel J, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(15 suppl):6s (Abstract 3).
52. Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral an-titumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2005; 64:7099-109.
53. Carter CA, Chen C, Brink C, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007; 59:183-95.
54. Liu B, Barrett T, Choyke P, et al. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl):676s (Abstract 17119).
55. Gatzemeier U, Blumenschein G, Fosella F. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006; 24(18 suppl):364s (Abstract 7002).
56. Steinbild S, Baas F, Gmehling D, et al. Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. J Clin Oncol 2005; 23(16 suppl):220s (Abstract 3115).
57. Eisen T, Ahmad T, Gore ME, et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J Clin Oncol 2005; 23(16 suppl):712s (Abstract 7508).
58. Adjei AA, Molina JR, Mandrekar S, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007; 13:2684-91.
59. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-605.
60. Socinski MA, Novello S, Sanchez JM. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. J Clin Oncol 2006; 24(18 suppl):364s (Abstract 7001).
61. Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007; 6:471-83.
62. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2006; 24(18 suppl): 363s (Abstract 7000).
63. Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. J Clin Oncol 2006; 24(18 suppl):368s (Abstract 7016).
64. De Boer R, Vansteenkiste J, Humblet Y, et al. Vandetanib with pemetrexed in patients with previously treated non-small cell lung cancer: An open label multi-center phase I study. J Clin Oncol 2007; 25(18 suppl):422s (Abstract 7654).
65. GlaxoSmithKline Clinical Trial Registry [Web site]. Available at: http://ctr.gsk. co.uk/Summary/lapatinib/studylist.asp. Accessed: July 20, 2008.
66. Kim H P, Han SW, Kim SH, et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther 2008; 7:607-15.
67. Scagliotti G. Proteasome inhibitors in lung cancer. Crit Rev Oncol Hematol 2006; 58:177-89.
68. Milano A, Iaffaioli RV, Caponigro F. The proteasome: A worthwhile target for the treatment of solid tumours? Eur J Cancer 2007; 43:1125-33.
69. Lara PN Jr, Koczywas M, Quinn DI, et al. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol 2006; 1:126-34.
70. Fanucchi M P, Fossella FV, Belt R, et al. Randomized phase II study of bortezo-mib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:5025-33.
71. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45.
72. Beevers CS, Li F, Liu L, et al. Curcumin inhibits the mammalian target of rapamy-cin-mediated signaling pathways in cancer cells. Int J Cancer 2006; 119:757-64.
73. Granville CA, Warfel N, Tsurutani J, et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 2007; 13:2281-9.
74. Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor Erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5:2676-84.
75. Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006; 12:5755-63.